Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin

Area of Science:

• Cardiology
• Rheumatology
• Vascular Biology

Background:

• Systemic sclerosis (SSc) is a connective tissue disease known for vascular lesions and organ fibrosis.
• Cardiac involvement in SSc is a significant indicator of poor prognosis.
• Myocardial involvement in SSc is frequently linked to microcirculation impairment and fibrosis.

Purpose of the Study:

• To investigate the mechanisms behind cardiac involvement in Systemic Sclerosis.
• To explore the role of microcirculation impairment in SSc-related myocardial dysfunction.
• To evaluate the efficacy of vasodilators in managing cardiac abnormalities in SSc.

Main Methods:

• Review of existing evidence on SSc cardiac involvement.
• Analysis of data linking microcirculation impairment to myocardial fibrosis.
• Assessment of the impact of vasodilators on cardiac perfusion and function.
• Utilisation of advanced imaging techniques like tissue Doppler echocardiography and MRI.

Main Results:

• Myocardial involvement in SSc is primarily driven by repeated focal ischemia due to microcirculation impairment.
• Abnormal vasoreactivity and structural vascular changes contribute to myocardial fibrosis and irreversible lesions.
• SSc patients exhibit impaired systolic and diastolic left and right ventricular function.
• Vasodilators, including calcium channel blockers and ACE inhibitors, improve cardiac perfusion and function.

Conclusions:

• Microcirculation impairment is a critical factor in the pathogenesis of cardiac dysfunction in Systemic Sclerosis.
• Therapeutic strategies targeting microcirculation may improve cardiac outcomes in SSc.
• Advanced quantitative methods confirm the benefits of vasodilators in addressing SSc-related cardiac issues.